On September 19, 2017, Becton, Dickinson, and Company (BDX), or BD, introduced a new pen needle for its pen injection devices. BD’s Ultra-Fine micro-pen needle 6 mm (millimeter) 32G launch has expanded the company’s needle offerings to healthcare practitioners, which should help BD enhance the efficiency of insulin delivery.
BD’s Ultra-Fine pen needle portfolio consists of 4 mm 32G (gauge), 5 mm 31G, 6 mm 32G, 8mm 31G, and 12.7 mm 29G needles. The newly launched needle began distribution in September 2017.
With this latest addition to the BD Ultra-Fine pen needle portfolio, BD will likely be advancing a strong product portfolio. BD has a strong product pipeline of devices and technology for the treatment of chronic diseases including diabetes.
Device features and benefits
Diabetes patients use insulin injections one or more times a day, and it’s possible to inject the insulin dose into a muscle instead of the subcutaneous fat of the patient’s abdomen, upper arm, buttocks, or thigh. With a shorter needle, the risk of injury is reduced.
Nabil Shabshab, worldwide president of Diabetes Care and Digital Health at BD, stated: “BD’s commitment to providing the best solutions possible for people with specific preferences…will help ensure that people with diabetes who prefer a 6 mm pen needle will be able to experience the quality and performance of BD Ultra-Fine pen needles.”
BD’s major competitors in the diabetes market include Medtronic (MDT), Edwards Lifesciences (EW), and Boston Scientific (BSX). Investors looking to gain exposure to BD can invest in the iShares Edge MSCI Min Vol USA ETF (USMV), which has ~1.5% of its total holdings in BD.